Compare AVNW & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | BMEA |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.4M | 96.9M |
| IPO Year | 2007 | 2021 |
| Metric | AVNW | BMEA |
|---|---|---|
| Price | $20.78 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $32.50 | $8.71 |
| AVG Volume (30 Days) | 109.3K | ★ 1.6M |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $453,497,000.00 | N/A |
| Revenue This Year | $5.73 | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $20.26 | ★ N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $15.80 | $0.87 |
| 52 Week High | $26.83 | $4.59 |
| Indicator | AVNW | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 55.16 |
| Support Level | $20.81 | $0.95 |
| Resistance Level | $21.52 | $1.42 |
| Average True Range (ATR) | 0.80 | 0.14 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 26.63 | 72.13 |
Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.